Torray Fund PFE trades
Robert Torray
Torray Fund Pfizer Inc stake
total: 71
Trades details
- Total transactions:
- 3
- New positions:
- 1
- Added:
- 1
- Reduced:
- 1
- Held since:
- 2025 Q2
- Held for:
- 5 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Torray Fund holds 575,000 Pfizer Inc (PFE) shares with a market value of roughly $15.05M accounting for 4.24% of the overall portfolio. To date, the estimated cost basis is nearly $23.86 for "buy" trades and estimated average "sell" price is $26.18. Torray Fund first purchased PFE in 2025 Q2, initially acquiring 501,300 shares. Since the initial investment in Pfizer Inc (PFE), Torray Fund has made 2 more transactions.
When did Torray Fund buy Pfizer Inc (PFE)?
Torray Fund first invested in Pfizer Inc (PFE) in 2025 Q2 at the reported quarter-end price of $23.49 per share.
What's the cost basis of Torray Fund's PFE stake?
The estimated cost basis for Pfizer Inc (PFE) stake is around $23.86 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $23.86
- Weighted AVG sell price:
- $26.18
Torray Fund's historical trades in Pfizer Inc
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
4.24%
|
575,000
|
$26.18
|
$15,053,500
|
-4.17% (-25,000)
|
-0.19%
|
|
2025 Q4
|
4.32%
|
600,000
|
$25.74
|
$15,444,000
|
+19.69% (+98,700)
|
+0.71%
|
|
2025 Q2
|
3.55%
|
501,300
|
$23.49
|
$11,775,537
|
new
|
+3.55%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.